ClinicalTrialsFinder
RecruitingNCT05342493

Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use

AJOVY Subcutaneous Injection Long-term Specified Use-results Survey

Sponsor

Otsuka Pharmaceutical Co., Ltd.

Enrollment

1,000 participants

Start Date

Apr 20, 2022

Study Type

OBSERVATIONAL

Conditions

Migraine Disorders

Summary

To evaluate the long-term safety of AJOVY in patients under actual use conditions and to specifically evaluate cardiovascular events. In addition, information on efficacy will be collected.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution for people with migraine disorders. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGFremanezumab 225 Mg/1.5 mL Subcutaneous Solution

The usual adult dose is 225 mg of fremanezumab (genetical recombination) administered subcutaneously as a single dose once every 4 weeks or 675 mg administered subcutaneously as a single dose once every 12 weeks.

Locations(1)

Pharmacovigilance Department

Osaka, Japan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05342493

Related Trials

MMA Embolization for Refractory Chronic Migraine

NCT067358339 locations

Migraine Attack Pain Phase Prediction Study

NCT064596351 location

Mind Body Balance for Pediatric Migraine

NCT047156852 locations

Determining the Utility of a Behavioral Intervention in Chronic Migraine

NCT054150201 location

Responding With Evidence and Access for Childhood Headaches

NCT0588962415 locations